Chemo-immunotherapy before chemoradiation for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests giving chemotherapy plus immunotherapy first, followed by standard chemoradiation, for people with advanced esophageal cancer that cannot be surgically removed. It aims to see if this approach improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have esophageal cancer that has spread to nearby lymph nodes but not to distant organs (except the lymph node above the collarbone is allowed).
- You have not had any prior chemotherapy, radiation, immunotherapy, or other cancer treatments.
- You are well enough to carry out daily activities (ECOG score 0 or 1).
- Your blood counts, kidney function, and liver function are within acceptable ranges.
- You can provide a tissue sample from your tumor (either fresh or stored within the last 6 months).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatment sequences for people with locally advanced esophageal cancer that cannot be removed with surgery. One group gets immunotherapy first, then chemoradiation; the other gets chemoradiation first, then immunotherapy. The goal is to find which order works better.
This trial compares two standard treatments for esophageal cancer that has responded to initial chemo-immunotherapy: surgery to remove the tumor or radiation combined with chemotherapy. The goal is to see which approach offers better outcomes and quality of life.
This study tests a combination of chemotherapy and immunotherapy before and after standard chemoradiation for people with locally advanced esophageal squamous cell carcinoma. It aims to see if this approach can improve outcomes with manageable side effects.
This trial tests a combination of an immunotherapy drug (adebrelimab), an immune-boosting agent (thymalfasin), and standard chemotherapy given before surgery for esophageal cancer. The goal is to see if this combination can shrink the tumor and improve outcomes after surgery.
This study tests whether giving radiation therapy based on how well the tumor responds to initial chemoimmunotherapy can improve outcomes for people with a certain type of esophageal cancer. The goal is to find a more personalized treatment approach that may be more effective and possibly reduce side effects.
This trial tests adding an immunotherapy drug called adebrelimab to standard chemotherapy before surgery for esophageal cancer that can be removed. It aims to see if this combination shrinks tumors more and improves outcomes.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.